Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a

Show simple item record

dc.contributor.author Moreau, Isabelle
dc.contributor.author Levis, John
dc.contributor.author Crosbie, Orla
dc.contributor.author Kenny-Walsh, Elizabeth
dc.contributor.author Fanning, Liam J.
dc.date.accessioned 2016-06-17T14:10:09Z
dc.date.available 2016-06-17T14:10:09Z
dc.date.issued 2008-07-09
dc.identifier.citation Moreau, I., Levis, J., Crosbie, O., Kenny-Walsh, E. and Fanning, L. J. (2008) 'Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a', Virology Journal, 5: 78. http://dx.doi.org/10.1186/1743-422X-5-78 en
dc.identifier.volume 5 en
dc.identifier.startpage 1 en
dc.identifier.endpage 15 en
dc.identifier.issn 1743-422X
dc.identifier.uri http://hdl.handle.net/10468/2755
dc.identifier.doi 10.1186/1743-422X-5-78
dc.description.abstract Pre-treatment HCV quasispecies complexity and diversity may predict response to interferon based anti-viral therapy. The objective of this study was to retrospectively (1) examine temporal changes in quasispecies prior to the start of therapy and (2) investigate extensively quasispecies evolution in a group of 10 chronically infected patients with genotype 3a, treated with pegylated alpha 2a-Interferon and ribavirin. The degree of sequence heterogeneity within the hypervariable region 1 was assessed by analyzing 20-30 individual clones in serial serum samples. Genetic parameters, including amino acid Shannon entropy, Hamming distance and genetic distance were calculated for each sample. Treatment outcome was divided into (1) sustained virological responders (SVR) and (2) treatment failure (TF).Our results indicate, (1) quasispecies complexity and diversity are lower in the SVR group, (2) quasispecies vary temporally and (3) genetic heterogeneity at baseline can be used to predict treatment outcome. We discuss the results from the perspective of replicative homeostasis. We discuss the results from the perspective of replicative homeostasis. en
dc.description.sponsorship Roche Pharmaceuticals, Ireland (unrestricted research grant) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Biomed Central en
dc.rights © 2008 Moreau et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited en
dc.rights.uri http://creativecommons.org/licenses/by/2.0/ en
dc.subject Hepatitis C virus en
dc.subject Interferon-alpha-2b plus ribavirin en
dc.subject Hypervariable region 1 en
dc.subject Antiviral therapy en
dc.subject Replicative homeostasis en
dc.subject Pegylated interferon en
dc.subject Sequence variability en
dc.subject Genetic diversity en
dc.subject Immune selection en
dc.subject Envelope protein en
dc.title Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Liam Fanning, Medicine Department, University College Cork, Cork, Ireland. +353-21-490-3000 Email: l.fanning@ucc.ie en
dc.internal.availability Full text available en
dc.date.updated 2013-01-18T15:07:01Z
dc.description.version Published Version en
dc.internal.rssid 160751920
dc.internal.wokid 000258511900002
dc.contributor.funder Roche Pharmaceuticals, Ireland en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Virology Journal en
dc.internal.copyrightchecked No.!!CORA!! en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress l.fanning@ucc.ie en
dc.identifier.articleid 78


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2008 Moreau et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited Except where otherwise noted, this item's license is described as © 2008 Moreau et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement